As the coronavirus pandemic spreads across the globe, putting unprecedented pressure on social, health, and economic systems, scientists are working around the clock to develop vaccine candidates in record time.
Intellectual property in the form of patented biosequences and chemical structures may play a role in inhibiting or antagonizing the virus factor to help researchers better understand the disease and bring treatments to fruition.
These extraordinary, collaborative, and fast-tracked scenarios playing out in labs all over the world raise some important questions for the biopharma patent community with regard to the state of innovation for the public good, today and in the future.
We will be covering the following topics